Correlation Between Hepion Pharmaceuticals and Blueprint Medicines

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Hepion Pharmaceuticals and Blueprint Medicines at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Hepion Pharmaceuticals and Blueprint Medicines into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Hepion Pharmaceuticals and Blueprint Medicines Corp, you can compare the effects of market volatilities on Hepion Pharmaceuticals and Blueprint Medicines and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Hepion Pharmaceuticals with a short position of Blueprint Medicines. Check out your portfolio center. Please also check ongoing floating volatility patterns of Hepion Pharmaceuticals and Blueprint Medicines.

Diversification Opportunities for Hepion Pharmaceuticals and Blueprint Medicines

-0.37
  Correlation Coefficient

Very good diversification

The 3 months correlation between Hepion and Blueprint is -0.37. Overlapping area represents the amount of risk that can be diversified away by holding Hepion Pharmaceuticals and Blueprint Medicines Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Blueprint Medicines Corp and Hepion Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Hepion Pharmaceuticals are associated (or correlated) with Blueprint Medicines. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Blueprint Medicines Corp has no effect on the direction of Hepion Pharmaceuticals i.e., Hepion Pharmaceuticals and Blueprint Medicines go up and down completely randomly.

Pair Corralation between Hepion Pharmaceuticals and Blueprint Medicines

Given the investment horizon of 90 days Hepion Pharmaceuticals is expected to under-perform the Blueprint Medicines. In addition to that, Hepion Pharmaceuticals is 2.27 times more volatile than Blueprint Medicines Corp. It trades about -0.04 of its total potential returns per unit of risk. Blueprint Medicines Corp is currently generating about 0.05 per unit of volatility. If you would invest  8,890  in Blueprint Medicines Corp on September 13, 2024 and sell it today you would earn a total of  557.00  from holding Blueprint Medicines Corp or generate 6.27% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Hepion Pharmaceuticals  vs.  Blueprint Medicines Corp

 Performance 
       Timeline  
Hepion Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Hepion Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Blueprint Medicines Corp 

Risk-Adjusted Performance

4 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Blueprint Medicines Corp are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of rather unfluctuating primary indicators, Blueprint Medicines may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Hepion Pharmaceuticals and Blueprint Medicines Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Hepion Pharmaceuticals and Blueprint Medicines

The main advantage of trading using opposite Hepion Pharmaceuticals and Blueprint Medicines positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Hepion Pharmaceuticals position performs unexpectedly, Blueprint Medicines can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Blueprint Medicines will offset losses from the drop in Blueprint Medicines' long position.
The idea behind Hepion Pharmaceuticals and Blueprint Medicines Corp pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.

Other Complementary Tools

Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance